Quince Therapeutics (QNCX) director takes 19,547 stock options in lieu of cash

Rhea-AI Filing Summary

Quince Therapeutics director Margaret McLoughlin reported receiving a new stock option award. On 01/02/2026, she was granted a Director Stock Option (Right to Buy) covering 19,547 shares of common stock at an exercise price of $3 per share. The filing shows this as an acquisition of derivative securities held directly.

According to the footnote, the option vests in equal quarterly installments over a one-year period. McLoughlin elected to receive this stock option grant in lieu of the 2026 annual director cash retainer under the company’s Outside Director Compensation Policy, meaning this award represents her director compensation rather than an open-market transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McLoughlin Margaret

(Last) (First) (Middle)

C/O QUINCE THERAPEUTICS, INC.

611 GATEWAY BLVD., SUITE 273

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Quince Therapeutics, Inc. [ QNCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$3	01/02/2026		A		19,547		(1)	01/02/2036	Common Stock	19,547	$0	19,547	D

Explanation of Responses:

1. The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy.

	/s/ Brendan Hannah as attorney-in-fact for Margaret McLoughlin	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Quince Therapeutics (QNCX) report for Margaret McLoughlin?

The filing reports that director Margaret McLoughlin acquired a Director Stock Option (Right to Buy) covering 19,547 shares of Quince Therapeutics common stock on 01/02/2026.

What are the key terms of Margaret McLoughlin’s new stock option at Quince Therapeutics (QNCX)?

The option gives McLoughlin the right to buy 19,547 shares of Quince Therapeutics common stock at an exercise price of $3 per share. It was reported as held directly and classified as an acquisition of derivative securities.

How does the Quince Therapeutics (QNCX) director stock option for Margaret McLoughlin vest?

The footnote states that the shares subject to the option vest in equal quarterly installments over a one-year period, so the award becomes exercisable in stages across that year.

Was Margaret McLoughlin’s Quince Therapeutics (QNCX) stock option grant part of her director compensation?

Yes. The filing explains that McLoughlin elected to receive stock options in lieu of the annual director cash retainer for 2026 under Quince Therapeutics’ Outside Director Compensation Policy.

How many derivative securities does Margaret McLoughlin own in Quince Therapeutics (QNCX) after this transaction?

After the reported transaction, McLoughlin beneficially owns 19,547 derivative securities (the director stock option) according to the Form 4.

Is the Quince Therapeutics (QNCX) stock option for Margaret McLoughlin a direct or indirect holding?

The Form 4 indicates the ownership form is Direct (D), meaning the option is held directly by Margaret McLoughlin rather than through an intermediary entity.